Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): Design of a community-based, longitudinal, clinical-pathological study

Zoe Arvanitakis, Robin L Brey, Jacob H. Rand, Julie A. Schneider, Sue E. Leurgans, Lei Yu, Aron S. Buchman, Konstantinos Arfanakis, Debra A. Fleischman, Patricia A. Boyle, David A. Bennett, Steven R. Levine

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The overall goal of the Antiphospholipid Antibodies, Brain Infarcts, and Cognitive and Motor Decline in Aging study is to test the hypothesis that antiphospholipid antibodies (aPL) are associated with an increased risk of pathologically proven brain infarcts and are related to cognitive and motor decline in aging. Putative biologic mechanisms underlying the association of aPL with infarcts and the relation of aPL with clinical outcomes of cognitive and motor impairment, including vascular and other processes, will be examined. The design of this longitudinal, clinical-pathologic study involves quantifying four aPL assays, and relating these to brain infarcts, and to cognitive and motor decline. Vascular mechanisms assessed using antemortem magnetic resonance neuroimaging and postmortem neuropathology, as well as nonvascular mechanisms of inflammation and blood-brain barrier permeability alterations will be examined as plausible mediators of the relation of aPL to cognitive and motor impairment. We will take advantage of antemortem biological specimens (longitudinally collected sera and plasma from which aPL, annexins, C-reactive protein, and matrix metalloproteinases will be quantified), and clinical, neuroimaging, and postmortem neuropathologic data from about 800 elderly, community-dwelling women and men who have agreed to brain autopsy at the time of death, participating in one of two ongoing studies of aging: the Religious Orders Study and the Memory and Aging Project.

Original languageEnglish (US)
Pages (from-to)73-84
Number of pages12
JournalNeuroepidemiology
Volume40
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Antiphospholipid Antibodies
Brain
Neuroimaging
Blood Vessels
Independent Living
Annexins
Clinical Studies
Cognitive Dysfunction
Blood-Brain Barrier
Matrix Metalloproteinases
C-Reactive Protein
Autopsy
Permeability
Magnetic Resonance Spectroscopy
Inflammation
Serum

Keywords

  • Annexins
  • Anticardiolipin antibodies
  • Antiphospholipid antibodies
  • Cerebrovascular disease
  • Cognitive and motor function

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA) : Design of a community-based, longitudinal, clinical-pathological study. / Arvanitakis, Zoe; Brey, Robin L; Rand, Jacob H.; Schneider, Julie A.; Leurgans, Sue E.; Yu, Lei; Buchman, Aron S.; Arfanakis, Konstantinos; Fleischman, Debra A.; Boyle, Patricia A.; Bennett, David A.; Levine, Steven R.

In: Neuroepidemiology, Vol. 40, No. 2, 02.2013, p. 73-84.

Research output: Contribution to journalArticle

Arvanitakis, Z, Brey, RL, Rand, JH, Schneider, JA, Leurgans, SE, Yu, L, Buchman, AS, Arfanakis, K, Fleischman, DA, Boyle, PA, Bennett, DA & Levine, SR 2013, 'Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): Design of a community-based, longitudinal, clinical-pathological study', Neuroepidemiology, vol. 40, no. 2, pp. 73-84. https://doi.org/10.1159/000342761
Arvanitakis, Zoe ; Brey, Robin L ; Rand, Jacob H. ; Schneider, Julie A. ; Leurgans, Sue E. ; Yu, Lei ; Buchman, Aron S. ; Arfanakis, Konstantinos ; Fleischman, Debra A. ; Boyle, Patricia A. ; Bennett, David A. ; Levine, Steven R. / Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA) : Design of a community-based, longitudinal, clinical-pathological study. In: Neuroepidemiology. 2013 ; Vol. 40, No. 2. pp. 73-84.
@article{4183b4dde6bc41d2a270e0926604d89e,
title = "Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): Design of a community-based, longitudinal, clinical-pathological study",
abstract = "The overall goal of the Antiphospholipid Antibodies, Brain Infarcts, and Cognitive and Motor Decline in Aging study is to test the hypothesis that antiphospholipid antibodies (aPL) are associated with an increased risk of pathologically proven brain infarcts and are related to cognitive and motor decline in aging. Putative biologic mechanisms underlying the association of aPL with infarcts and the relation of aPL with clinical outcomes of cognitive and motor impairment, including vascular and other processes, will be examined. The design of this longitudinal, clinical-pathologic study involves quantifying four aPL assays, and relating these to brain infarcts, and to cognitive and motor decline. Vascular mechanisms assessed using antemortem magnetic resonance neuroimaging and postmortem neuropathology, as well as nonvascular mechanisms of inflammation and blood-brain barrier permeability alterations will be examined as plausible mediators of the relation of aPL to cognitive and motor impairment. We will take advantage of antemortem biological specimens (longitudinally collected sera and plasma from which aPL, annexins, C-reactive protein, and matrix metalloproteinases will be quantified), and clinical, neuroimaging, and postmortem neuropathologic data from about 800 elderly, community-dwelling women and men who have agreed to brain autopsy at the time of death, participating in one of two ongoing studies of aging: the Religious Orders Study and the Memory and Aging Project.",
keywords = "Annexins, Anticardiolipin antibodies, Antiphospholipid antibodies, Cerebrovascular disease, Cognitive and motor function",
author = "Zoe Arvanitakis and Brey, {Robin L} and Rand, {Jacob H.} and Schneider, {Julie A.} and Leurgans, {Sue E.} and Lei Yu and Buchman, {Aron S.} and Konstantinos Arfanakis and Fleischman, {Debra A.} and Boyle, {Patricia A.} and Bennett, {David A.} and Levine, {Steven R.}",
year = "2013",
month = "2",
doi = "10.1159/000342761",
language = "English (US)",
volume = "40",
pages = "73--84",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA)

T2 - Design of a community-based, longitudinal, clinical-pathological study

AU - Arvanitakis, Zoe

AU - Brey, Robin L

AU - Rand, Jacob H.

AU - Schneider, Julie A.

AU - Leurgans, Sue E.

AU - Yu, Lei

AU - Buchman, Aron S.

AU - Arfanakis, Konstantinos

AU - Fleischman, Debra A.

AU - Boyle, Patricia A.

AU - Bennett, David A.

AU - Levine, Steven R.

PY - 2013/2

Y1 - 2013/2

N2 - The overall goal of the Antiphospholipid Antibodies, Brain Infarcts, and Cognitive and Motor Decline in Aging study is to test the hypothesis that antiphospholipid antibodies (aPL) are associated with an increased risk of pathologically proven brain infarcts and are related to cognitive and motor decline in aging. Putative biologic mechanisms underlying the association of aPL with infarcts and the relation of aPL with clinical outcomes of cognitive and motor impairment, including vascular and other processes, will be examined. The design of this longitudinal, clinical-pathologic study involves quantifying four aPL assays, and relating these to brain infarcts, and to cognitive and motor decline. Vascular mechanisms assessed using antemortem magnetic resonance neuroimaging and postmortem neuropathology, as well as nonvascular mechanisms of inflammation and blood-brain barrier permeability alterations will be examined as plausible mediators of the relation of aPL to cognitive and motor impairment. We will take advantage of antemortem biological specimens (longitudinally collected sera and plasma from which aPL, annexins, C-reactive protein, and matrix metalloproteinases will be quantified), and clinical, neuroimaging, and postmortem neuropathologic data from about 800 elderly, community-dwelling women and men who have agreed to brain autopsy at the time of death, participating in one of two ongoing studies of aging: the Religious Orders Study and the Memory and Aging Project.

AB - The overall goal of the Antiphospholipid Antibodies, Brain Infarcts, and Cognitive and Motor Decline in Aging study is to test the hypothesis that antiphospholipid antibodies (aPL) are associated with an increased risk of pathologically proven brain infarcts and are related to cognitive and motor decline in aging. Putative biologic mechanisms underlying the association of aPL with infarcts and the relation of aPL with clinical outcomes of cognitive and motor impairment, including vascular and other processes, will be examined. The design of this longitudinal, clinical-pathologic study involves quantifying four aPL assays, and relating these to brain infarcts, and to cognitive and motor decline. Vascular mechanisms assessed using antemortem magnetic resonance neuroimaging and postmortem neuropathology, as well as nonvascular mechanisms of inflammation and blood-brain barrier permeability alterations will be examined as plausible mediators of the relation of aPL to cognitive and motor impairment. We will take advantage of antemortem biological specimens (longitudinally collected sera and plasma from which aPL, annexins, C-reactive protein, and matrix metalloproteinases will be quantified), and clinical, neuroimaging, and postmortem neuropathologic data from about 800 elderly, community-dwelling women and men who have agreed to brain autopsy at the time of death, participating in one of two ongoing studies of aging: the Religious Orders Study and the Memory and Aging Project.

KW - Annexins

KW - Anticardiolipin antibodies

KW - Antiphospholipid antibodies

KW - Cerebrovascular disease

KW - Cognitive and motor function

UR - http://www.scopus.com/inward/record.url?scp=84867677767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867677767&partnerID=8YFLogxK

U2 - 10.1159/000342761

DO - 10.1159/000342761

M3 - Article

C2 - 23095514

AN - SCOPUS:84867677767

VL - 40

SP - 73

EP - 84

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

IS - 2

ER -